98%
921
2 minutes
20
: Cryoglobulinemia (CG) syndrome is a heterogeneous condition characterized by the presence of cryoglobulins in serum, often leading to vasculitis with protean clinical manifestations. Understanding the presentation of cryoglobulinemia-related symptoms based on cryoprecipitate levels, GC type, and severity at diagnosis is essential for effective management. Hence, this study aimed to provide a comprehensive analysis of patients with positive cryoglobulin detection to investigate these aspects. : We conducted a retrospective review of clinical charts from patients with positive cryoglobulin detection at Colmar Hospital between May 2015 and April 2019. : Among 166 patients with positive cryoglobulins, the median cryoprecipitate value was 37 mg/L [IQR: 25-70], with 62% of patients below the 50 mg/L threshold. High cryoprecipitate levels were associated with C-virus hepatitis ( = 0.0007), increased fatigue ( = 0.001), fever ( = 0.0013), weight loss ( = 0.028), and musculoskeletal symptoms ( = 0.002). These patients also exhibited decreases in complement fractions (-values 0.017 to 0.006). At the end of the one-year follow-up, they required frequent renal replacement therapy ( < 0.0001) and had a higher mortality rate ( = 0.02). Based on the CG type, patients with type I GC had splenomegaly ( = 0.039) and hemopathy ( = 0.001). According to severity at initial presentation, the severe patients had more purpura ( < 0.001), Raynaud's phenomenon ( = 0.039), and leukocytoclastic vasculitis on skin biopsy ( < 0.001), along with higher cryoprecipitate levels ( = 0.011). Multivariate analysis identified purpura (OR: 10.25), hematological malignancy (OR: 7.06), Raynaud's phenomenon (OR: 6.41), and cryoprecipitate levels (OR: 1.02) as significant markers of disease severity serving for the development of a severity score for clinical practice. : This study identifies severity markers in patients with positive cryoprecipitate and proposes a score related to severity at diagnosis.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11765962 | PMC |
http://dx.doi.org/10.3390/jcm14020556 | DOI Listing |
Transfus Med
August 2025
Division of Transfusion Medicine, Suzhou Blood Center, Suzhou, China.
This systematic review and meta-analysis aim to evaluate the changes in coagulation factor and bacterial contamination by extending the preservation period of thawed cryoprecipitate for 5 days at refrigerated temperatures. Literature searches were conducted from three different databases, and the literature was screened according to the inclusion criteria. The quality of the literature was assessed using the Risk of Bias in Non-randomised Studies-of Interventions (ROBINS-I) tool, and a meta-analysis was conducted using RevMan5.
View Article and Find Full Text PDFWe report a clinical case of severe and prolonged hypofibrinogenemia caused by envenomation from Protobothrops cornutus, an pit viper species found mainly in Vietnam and parts of southern China. A 60-year-old woman was bitten while hiking in Cuc Phuong national forest of Ninh Binh province, Vietnam. Although WHO guidelines discourage antivenom administration for minor coagulation abnormalities, in this case, the decision was made due to a fibrinogen level <1.
View Article and Find Full Text PDFJ Pediatr Hematol Oncol
July 2025
Department of Pediatrics, Pediatric Hematology-Oncology, The University of Texas MD Anderson Cancer Center.
Background: Cryoprecipitate is often used to prevent and treat complications associated with low fibrinogen levels in pediatric leukemia patients. Cryoprecipitate, rich in fibrinogen, is administered to augment fibrinogen levels and mitigate the risk of bleeding in these patients. The use of cryoprecipitate is often strategic, involving both prophylactic measures and interventions in response to bleeding events.
View Article and Find Full Text PDFJ Trauma Acute Care Surg
July 2025
From the Department of Surgery (J.-M.V.G., T.W.C., B.A.C.), McGovern Medical School, University of Texas Health Science Center, Houston; and Joint Trauma System (J.-M.V.G., J.M.G.), Defense Health Agency, Joint Base San Antonio-Fort Sam Houston, Texas.
Background: Empiric cryoprecipitate administration has recently failed to show survival benefit in hemorrhaging trauma patients. However, a recent Trauma Quality Improvement Program query suggested a survival benefit in massive transfusions when administering 1 U of cryoprecipitate to every 7 to 8 U of red blood cells (RBCs). We describe transfusion ratios when cryoprecipitate was indicated by viscoelastic testing (VET) and evaluated whole blood (WB)'s impact on this ratio.
View Article and Find Full Text PDFTransfus Med Hemother
April 2025
Division of Transfusion Medicine, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
Introduction: Originally developed as a form of factor VIII concentrate, cryoprecipitate's primary clinical use has changed to treat fibrinogen deficiency as highlighted by recent approval of pathogen-reduced cryoprecipitated fibrinogen concentrates. The methodology by which frozen plasma is thawed during cryoprecipitate manufacturing is not standardized. This study compared plasma thawing techniques on cryoprecipitate fibrinogen and factor VIII levels.
View Article and Find Full Text PDF